- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi's Anemia, Thalassemia, Sickle Cell Disease
- Interventions
- Melphalan
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 2,476
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Electronic Health Record Review, Spiritual Therapy, Survey Administration
- Other · Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Epidermolysis Bullosa
- Interventions
- Thymoglobulin, Cyclophosphamide, Fludarabine, Total Body Irradiation, Bone marrow infusion, Tacrolimus, Mycophenolate Mofetil, Donor mesenchymal stem cell infusions, Busulfan
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hematologic Malignancy
- Interventions
- Fructooligosaccharide, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Leukemia
- Interventions
- Bortezomib, Pravastatin
- Drug
- Lead sponsor
- Reuven Schore
- Other
- Eligibility
- 22 Months to 21 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Myeloma
- Interventions
- Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
- Biological · Other · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Philadelphia, Pennsylvania
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Neoplasm, Plasma Cell Dyscrasia, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Plasma Cell Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, Total body irradiation, Tacrolimus, Mycophenolate mofetil
- Drug · Radiation
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
- Procedure · Other · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2075
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bone Marrow Transplantation Recipient, Cord Blood Transplant Recipient, Hematopoietic Cell Transplantation Recipient
- Interventions
- Eltrombopag Olamine, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Bendamustine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Graft vs Host Disease
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2006
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Cardiovascular Complications, Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Metabolic Syndrome
- Interventions
- Not listed
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 9 Years to 21 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
- Interventions
- Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
- Interventions
- Neihulizumab Treatment, Conventional Treatment
- Biological
- Lead sponsor
- AbGenomics B.V Taiwan Branch
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
- Interventions
- Eye exam
- Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Severe Combined Immune Deficiency (SCID)
- Interventions
- Sirolimus, Busulfan, Horse -Anti-thymocyte, G-CSF, Total Body Irradiation (TBI)
- Drug · Radiation
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 3 Years to 40 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Interventions
- Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 280
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Busulfan IV, Melphalan IV
- Drug
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Graft Versus Host Disease, Systemic Scleroderma
- Interventions
- imatinib mesylate, rituximab
- Drug · Biological
- Lead sponsor
- Lee, Stephanie
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Tampa, Florida + 7 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide, Cyclosporin, Mesenchymal Stem Cell Transplantation, Busulfan
- Other · Radiation · Drug + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2007
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Leukemia, Myeloid, Myelodysplastic Syndromes
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Lymphoma
- Interventions
- filgrastim, carboplatin, carmustine, cytarabine, etoposide, ifosfamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 60 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hematologic Malignancies, Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Disease
- Interventions
- Sirolimus, Tacrolimus
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts